STAT+: Why the closure of an FDA office may impact generics manufacturers — and everyday Americans
Why the closure of an FDA office may impact generics manufacturers — and everyday Americans.
Amid the hard-to-follow cutbacks at the U.S. Food and Drug Administration, a little-known but important office was eliminated — and the implications will be felt not only by drugmakers, but consumers.
The Division of Policy Development in the Office of Generic Drug Policy, which was created more than a decade ago, was responsible for a host of activities that were central to ensuring generic drugs were approved properly for the American market.
Now, though, that goal may be in jeopardy.
